CollPlant is building on its progress in 2016 by increasing its distribution of VergenixFG and actively pursuing potential partnerships for its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We forecast the need for a fund-raising this year and management indicated in the Q1 results that it believes it has sufficient funds into Q317. We have slightly increased our rNPV to $70m (NIS248m) as a result of rolling our model forward and using the Q1 cash position.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs